09.15.15
Holt, Mich.-based orthopedic device design and manufacturing company Orchid Orthopedic Solutions has acquired Alhenia AG, which makes coated orthopedic implants. Alhenia is headquartered in Switzerland.
In addition to coating technologies, geographic reach and an expanded customer base, Orchid also gains an integrated local supply chain in Europe—from castings and forgings to fully finished, coated and packaged implants—with this acquisition.
Alhenia’s coating portfolio includes coatings on peek and polyethylene, ceramic coatings, cold spray coatings, titanium on metal and ceramic substrates and anti bacterial coatings. Alhenia also has many years of experience machining implants and instruments along with a wide variety of finishing capabilities to complete the entire value stream for orthopedic components. Alhenia is based in Switzerland and employs approximately 60 people.
“Orchid is very pleased to have the Alhenia founders and their employees join the Orchid team,” said Mike Miller, CEO of Orchid. “With this strategic acquisition, Orchid is clearly the world technology leader in coating services for the global orthopedic market.”
“Adding Alhenia’s coating and machining capabilities to Orchid further strengthens Orchid’s market position in the orthopedic market in Europe,” said Christopher Norbye, Orchid’s international executive vice president.
”We are convinced that Orchid is the perfect platform to further expand the technologies and markets that Alhenia has developed in the last years, offering attractive opportunities for our specialized team and customers in the near future,” Jorge Garcia and Armando Salito, the founders of Alhenia, said in a prepared statement.
Orchid is a medical device design and manufacturing company for orthopedic device companies. The company was recently selected to participate as the U.S. Food and Drug Administration’s sole regulatory consulting firm in the agency’s new submission tracking initiative. (Editor’s note: For more information on the FDA’s new tracking initiative, see Washington Roundup on page 18.)
In addition to coating technologies, geographic reach and an expanded customer base, Orchid also gains an integrated local supply chain in Europe—from castings and forgings to fully finished, coated and packaged implants—with this acquisition.
Alhenia’s coating portfolio includes coatings on peek and polyethylene, ceramic coatings, cold spray coatings, titanium on metal and ceramic substrates and anti bacterial coatings. Alhenia also has many years of experience machining implants and instruments along with a wide variety of finishing capabilities to complete the entire value stream for orthopedic components. Alhenia is based in Switzerland and employs approximately 60 people.
“Orchid is very pleased to have the Alhenia founders and their employees join the Orchid team,” said Mike Miller, CEO of Orchid. “With this strategic acquisition, Orchid is clearly the world technology leader in coating services for the global orthopedic market.”
“Adding Alhenia’s coating and machining capabilities to Orchid further strengthens Orchid’s market position in the orthopedic market in Europe,” said Christopher Norbye, Orchid’s international executive vice president.
”We are convinced that Orchid is the perfect platform to further expand the technologies and markets that Alhenia has developed in the last years, offering attractive opportunities for our specialized team and customers in the near future,” Jorge Garcia and Armando Salito, the founders of Alhenia, said in a prepared statement.
Orchid is a medical device design and manufacturing company for orthopedic device companies. The company was recently selected to participate as the U.S. Food and Drug Administration’s sole regulatory consulting firm in the agency’s new submission tracking initiative. (Editor’s note: For more information on the FDA’s new tracking initiative, see Washington Roundup on page 18.)